scholarly journals The safety of beta-blocker use in chronic obstructive pulmonary disease patients with respiratory failure in the intensive care unit

2014 ◽  
Vol 9 (1) ◽  
pp. 8 ◽  
Author(s):  
Feyza Kargin ◽  
Huriye Berk Takir ◽  
Cuneyt Salturk ◽  
Nezihe Goksenoglu ◽  
Can Karabay ◽  
...  
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Intensive Care Unit ◽  
Intensive Care ◽  
Respiratory Failure ◽  
Pulmonary Disease ◽  
Beta Blocker ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease

scholarly journals Moxifloxacin in Chronic Obstructive Pulmonary Disease: Pharmacokinetics and Penetration into Bronchial Secretions in Ward and Intensive Care Unit Patients

2019 ◽  
Vol 63 (3) ◽  
Author(s):  
Maria Sionidou ◽  
Katerina Manika ◽  
Georgia Pitsiou ◽  
Paschalina Kontou ◽  
Kalliopi Chatzika ◽  
...  
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Intensive Care Unit ◽  
Intensive Care ◽  
Pulmonary Disease ◽  
Pharmacokinetic Profile ◽  
Pharmacokinetic Parameters ◽  
Chronic Obstructive ◽  
Icu Patients ◽  
Obstructive Pulmonary Disease ◽  
Bronchial Secretions

ABSTRACT This study aimed to evaluate the pharmacokinetic profile of moxifloxacin (MXF) in serum and sputum/bronchial secretions of 22 patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD) hospitalized in the ward and intensive care unit (ICU). The data showed that ICU patients had lower concentrations in secretions (P = 0.01). However, no other statistically significant differences were observed in pharmacokinetic parameters and penetration in secretions between ward and ICU patients. MXF showed a favorable pharmacokinetic profile, and the pharmacodynamic targets for common pathogens for AECOPD were achieved.

Sign in / Sign up

Export Citation Format

Share Document